CBIO
Crescent Biopharma
CBIO
CBIO
58 hedge funds and large institutions have $82.9M invested in Crescent Biopharma in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.01% more ownership
Funds ownership: 0.54% → 0.55% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
Holders
58
Holding in Top 10
–
Calls
$382K
Puts
$69K
Top Buyers
| 1 | +$295K | |
| 2 | +$263K | |
| 3 | +$253K | |
| 4 |
AO
Advisor OS
Chicago,
Illinois
|
+$238K |
| 5 |
MA
MJP Associates
Farmington,
Connecticut
|
+$238K |
Top Sellers
| 1 | -$714K | |
| 2 | -$181K | |
| 3 | -$129K | |
| 4 |
Two Sigma Advisers
New York
|
-$126K |
| 5 |
Axa
Paris,
France
|
-$90.6K |